Endocrine Month in Review: September 2021

September's endocrine month in review features news related to diabetes, polycystic ovary syndrome, warnings from the FDA and FTC, and a column from Dr. Paul Thompson.

Top Stories of September 2021:

  1. North American Menopause Society Releases Updated Osteoporosis Guidance
    The organization's first update since their 2010 position statement, the osteoporosis position statement reflects more than a decade of advances in knowledge related to diagnosis and management of osteoporosis.
  2. FDA Warns 10 Companies For Illegally Marketing Supplements Claiming to Treat Diabetes
    The FDA and FTC posted warnings to 10 companies for violating the Federal Food, Drug, and Cosmetic Act by selling dietary supplements claiming to cure, treat, mitigate, or prevent diabetes.
  3. Patients with Diabetes More Likely to Experience Sexual Dysfunction
    New data describes risk factors associated with increased prevalence of sexual dysfunction among patients with type 1 and type 2 diabetes.
  4. Why Cardiologists Should Become Diabetologists, With Paul D. Thompson, MD
    Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.
  5. Treating Polycystic Ovary Syndrome Costs $8 Billion in US Annually
    A meta-analysis builds upon previous research and provides new insight into the total costs of diagnosis and treating PCOS as well as the costs of treating PCOS-related comorbidities.